XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | 0.25 | -0.04 | -116.00% | $207.7M | ❌ Miss | +1.65% | +2.72% | — |
| 2026-02-24 | Q4 2025 | 0.22 | -0.07 | -131.82% | $211.6M | ❌ Miss | +5.07% | +2.36% | -4.70% |
| 2025-11-04 |
| Q3 2025 |
| 0.62 |
| -0.80 |
| -229.03% |
| $192.1M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | 0.42 | 0.40 | -4.76% | $180.9M | ❌ Miss | +0.72% | +9.89% | +21.05% |
| 2025-02-25 | Q4 2024 | 0.52 | 0.27 | -48.08% | $174.2M | ❌ Miss | -2.74% | -3.54% | -1.19% |
| 2024-11-04 | Q3 2024 | 0.44 | 0.69 | +56.82% | $175.7M | ✅ Beat | +0.12% | +5.50% | +7.06% |
| 2024-08-06 | Q2 2024 | 0.39 | 0.36 | -7.69% | $168.3M | ❌ Miss | +14.49% | +20.70% | +23.31% |
| 2024-05-08 | Q1 2024 | 0.38 | 0.00 | -100.00% | $143.6M | ❌ Miss | -4.15% | -8.18% | -16.10% |
Showing last 8 quarters.